
SGLT2 inhibitors (SGLT2i) reduce kidney disease progression in insulin-deficient diabetes. A study of 12,530 patients found SGLT2i use lowered the risk of significant eGFR decline (HR 0.79, p<0.001) and serum creatinine doubling (HR 0.76, p<0.001). Albuminuria also improved in 51% of users. Although diabetic ketoacidosis (DKA) risk was slightly higher (2.81% vs. 2.19%, p=0.03), SGLT2i showed strong renal benefits across subgroups.
Like
Save
Share